Related Experiment Video
Updated: May 26, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
Combination pitavastatin-ezetimibe therapy for hypercholesterolemia and mixed dyslipidemia: a systematic review and
Muhammad Sharjeel Abbas1, Asia Batool2, Muhammad Hussain3
1Department of Medicine, Gomal Medical College Khyber Medical University, Peshawar, Pakistan.
Insights
Pitavastatin combined with ezetimibe significantly lowers non-high-density lipoprotein cholesterol, total cholesterol, and Apolipoprotein B compared to pitavastatin alone. This combination therapy is a promising option for patients needing intensive low-density lipoprotein cholesterol management.
Area of Science:
- Cardiology
- Pharmacology
- Evidence-Based Medicine
Background:
- Dyslipidemia is a primary driver of atherosclerotic cardiovascular disease.
- Many patients fail to reach target low-density lipoprotein cholesterol (LDL-C) levels with statin monotherapy.
- Investigating complementary therapies is crucial for effective dyslipidemia management.
Conclusions:
- Pitavastatin plus ezetimibe offers enhanced lipid-lowering effects, particularly for LDL-C.
- This combination may be an effective supplementary strategy for patients requiring more intensive lipid management.
- Further research is warranted due to the limited evidence base.
Background:
Dyslipidemia is a prevalent and major contributor to atherosclerotic cardiovascular disease; however, many patients do not achieve the recommended low-density lipoprotein cholesterol goals with statin monotherapy. Thus, the efficacy of complementary therapeutic options must be investigated.
Objective:
To evaluate the lipid-lowering efficacy and safety of pitavastatin combined with ezetimibe versus pitavastatin monotherapy in adults with hypercholesterolemia or mixed dyslipidemia.
Methods:
A systematic search of PubMed, Embase, Cochrane Library, and Scopus (November 2025) identified randomized controlled trials that compared pitavastatin 2 mg or 4 mg plus ezetimibe 10 mg with pitavastatin 2 mg alone. The protocol for this systematic review and meta-analysis was prospectively registered in PROSPERO. A random-effects meta-analysis was used to pool lipid and safety outcomes. The risk of bias was assessed using RoB 2, and the certainty of evidence was graded using the GRADE tool.
Results:
Non-high-density lipoprotein cholesterol, total cholesterol, and Apolipoprotein B. Changes in high-density lipoprotein cholesterol and triglyceride levels were modest but more pronounced at week 12.
Conclusion:
Combination therapy offers an apparent enhancement in lipid lowering and may serve as an effective supplementary option for patients who require more intensive low-density lipoprotein cholesterol management. However, the limited evidence warrants further research.
Protocol Registration:
www.crd.york.ac.uk/prospero identifier is CRD420251233057.
Related Concept Videos
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Atherosclerosis III: Management
Coronary Artery Disease V: Interprofessional Care
Cholesterol: Significance and Regulation
Considering cholesterol and...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Peripheral Artery Disease III: Interprofessional Care
